Prognostic and Predictive Values and Statistical Interactions in the Era of Targeted Treatment.
The current era of targeted treatment has accelerated the interest in studying gene-treatment, gene-gene, and gene-environment interactions using statistical models in the health sciences. Interactions are incorporated into models as product terms of risk factors. The statistical significance of interactions is traditionally examined using a likelihood ratio test (LRT). Epidemiological and clinical studies also evaluate interactions in order to understand the prognostic and predictive values of genetic factors. However, it is not clear how different types and magnitudes of interaction effects are related to prognostic and predictive values. The contribution of interaction to prognostic values can be examined via improvements in the area under the receiver operating characteristic curve due to the inclusion of interaction terms in the model (ΔAUC). We develop a resampling based approach to test the significance of this improvement and show that it is equivalent to LRT. Predictive values provide insights into whether carriers of genetic factors benefit from specific treatment or preventive interventions relative to noncarriers, under some definition of treatment benefit. However, there is no unique definition of the term treatment benefit. We show that ΔAUC and relative excess risk due to interaction (RERI) measure predictive values under two specific definitions of treatment benefit. We investigate the properties of LRT, ΔAUC, and RERI using simulations. We illustrate these approaches using published melanoma data to understand the benefits of possible intervention on sun exposure in relation to the MC1R gene. The goal is to evaluate possible interventions on sun exposure in relation to MC1R.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Jaya M
JM
Satagopan
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Alexia
A
Iasonos
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Qin
Q
Zhou
D004198:Disease Susceptibility; D059647:Gene-Environment Interaction; D006579:Heterozygote; D006801:Humans; D016013:Likelihood Functions; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics* / Q000517:prevention & control; D008957:Models, Genetic; D015233:Models, Statistical; D016017:Odds Ratio; D011237:Predictive Value of Tests; D011379:Prognosis; D012372:ROC Curve; D044102:Receptor, Melanocortin, Type 1 / Q000235:genetics; D012307:Risk Factors; D012867:Skin / Q000378:metabolism / Q000528:radiation effects; D013472:Sunlight / Q000009:adverse effects; D016896:Treatment Outcome
D044102:Receptor, Melanocortin, Type 1
area under the receiver operating characteristic curve; likelihood ratio test; relative excess risk due to interaction (RERI); resampling; treatment benefit